These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17001815)

  • 1. Canadian Association of Neurosciences Review: polyglutamine expansion neurodegenerative diseases.
    Truant R; Raymond LA; Xia J; Pinchev D; Burtnik A; Atwal RS
    Can J Neurol Sci; 2006 Aug; 33(3):278-91. PubMed ID: 17001815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting several CAG expansion diseases by a single antisense oligonucleotide.
    Evers MM; Pepers BA; van Deutekom JC; Mulders SA; den Dunnen JT; Aartsma-Rus A; van Ommen GJ; van Roon-Mom WM
    PLoS One; 2011; 6(9):e24308. PubMed ID: 21909428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino acid sequences flanking polyglutamine stretches influence their potential for aggregate formation.
    Nozaki K; Onodera O; Takano H; Tsuji S
    Neuroreport; 2001 Oct; 12(15):3357-64. PubMed ID: 11711886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology.
    Stoyas CA; La Spada AR
    Handb Clin Neurol; 2018; 147():143-170. PubMed ID: 29325609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract.
    Wellington CL; Ellerby LM; Hackam AS; Margolis RL; Trifiro MA; Singaraja R; McCutcheon K; Salvesen GS; Propp SS; Bromm M; Rowland KJ; Zhang T; Rasper D; Roy S; Thornberry N; Pinsky L; Kakizuka A; Ross CA; Nicholson DW; Bredesen DE; Hayden MR
    J Biol Chem; 1998 Apr; 273(15):9158-67. PubMed ID: 9535906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases.
    Ghosh S; Feany MB
    Hum Mol Genet; 2004 Sep; 13(18):2011-8. PubMed ID: 15254017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract.
    Yue S; Serra HG; Zoghbi HY; Orr HT
    Hum Mol Genet; 2001 Jan; 10(1):25-30. PubMed ID: 11136710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias.
    Trottier Y; Lutz Y; Stevanin G; Imbert G; Devys D; Cancel G; Saudou F; Weber C; David G; Tora L
    Nature; 1995 Nov; 378(6555):403-6. PubMed ID: 7477379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
    Truant R; Atwal RS; Burtnik A
    Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide models for inherited neurodegenerative disorders: conformation and aggregation properties of long polyglutamine peptides with and without interruptions.
    Sharma D; Sharma S; Pasha S; Brahmachari SK
    FEBS Lett; 1999 Jul; 456(1):181-5. PubMed ID: 10452554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spinocerebellar ataxia type 1--modeling the pathogenesis of a polyglutamine neurodegenerative disorder in transgenic mice.
    Clark HB; Orr HT
    J Neuropathol Exp Neurol; 2000 Apr; 59(4):265-70. PubMed ID: 10759181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases.
    Branco J; Al-Ramahi I; Ukani L; Pérez AM; Fernandez-Funez P; Rincón-Limas D; Botas J
    Hum Mol Genet; 2008 Feb; 17(3):376-90. PubMed ID: 17984172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studying polyglutamine diseases in Drosophila.
    Xu Z; Tito AJ; Rui YN; Zhang S
    Exp Neurol; 2015 Dec; 274(Pt A):25-41. PubMed ID: 26257024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAT10 protein binds to polyglutamine proteins and modulates their solubility.
    Nagashima Y; Kowa H; Tsuji S; Iwata A
    J Biol Chem; 2011 Aug; 286(34):29594-600. PubMed ID: 21757738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinocerebellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase.
    Koshy B; Matilla T; Burright EN; Merry DE; Fischbeck KH; Orr HT; Zoghbi HY
    Hum Mol Genet; 1996 Sep; 5(9):1311-8. PubMed ID: 8872471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS.
    Bonini NM; Gitler AD
    J Mol Neurosci; 2011 Nov; 45(3):676-83. PubMed ID: 21660502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Properties of polyglutamine expansion in vitro and in a cellular model for Huntington's disease.
    Lunkes A; Trottier Y; Fagart J; Schultz P; Zeder-Lutz G; Moras D; Mandel JL
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1013-9. PubMed ID: 10434300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ataxin 1 and ataxin 3 in neuronal intranuclear inclusion disease.
    Lieberman AP; Trojanowski JQ; Leonard DG; Chen KL; Barnett JL; Leverenz JB; Bird TD; Robitaille Y; Malandrini A; Fischbeck KH
    Ann Neurol; 1999 Aug; 46(2):271-3. PubMed ID: 10443897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis.
    Lee T; Li YR; Chesi A; Hart MP; Ramos D; Jethava N; Hosangadi D; Epstein J; Hodges B; Bonini NM; Gitler AD
    Neurology; 2011 Jun; 76(24):2062-5. PubMed ID: 21562248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.